Antibody Drug Conjugates in Thoracic Malignancies

It has been several years since Federal Drug Administration (FDA) approval of a new cytotoxic in thoracic malignancies. Nab-paclitaxel was approved for non-small-cell lung cancer (NSCLC) in 2012, pemetrexed for malignant pleural mesothelioma (MPM) in 2004 and topotecan for small-cell lung cancer (SCLC) in 1998. In the first half of the current decade targeted therapy was the major advancement and in the latter half of this decade immunotherapy has been the focus. Antibody-drug conjugates (ADCs) are a new type of cytotoxic, which target particular cancer cell surface proteins and may aid in stimulating anti-tumor immunity.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research